[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370461-105":59,"doc-detail-370461-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","super-enhancerdriven-efna1-fuels-tumor-progression-in-cervical-cancer-via-the-fosl2-srcaktstat3-axis","Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis","","Super-enhancers (SEs) amplify oncogene expression, yet their function in cervical cancer (CC) is insufficiently defined. Integrated epigenomic and transcriptomic profiling of paired tumor and normal tissues reveals a tumor-specific SE at the EFNA1 locus that drives EFNA1 transcription. Mechanistically, the EFNA1-SE contains FOSL2 consensus motifs; FOSL2 knockdown reduces luciferase activity and H3K27ac at the SE. EFNA1 depletion suppresses CC proliferation, migration, and tumor growth, and EFNA1 cis-interacts with EphA2 to activate Src/AKT/STAT3 signaling, attenuated by pathway inhibitors in vitro and in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/super-enhancerdriven-efna1-fuels-tumor-progression-in-cervical-cancer-via-the-fosl2-srcaktstat3-axis/370461/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/super-enhancerdriven-efna1-fuels-tumor-progression-in-cervical-cancer-via-the-fosl2-srcaktstat3-axis/370461.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What discovery does the study make about super-enhancers in cervical cancer?","Question",{"text":112,"@type":113},"It identifies a tumor-specific super-enhancer at the EFNA1 locus that drives EFNA1 expression in cervical cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does FOSL2 regulate the EFNA1 super-enhancer?",{"text":117,"@type":113},"The EFNA1-SE region contains FOSL2 consensus sequences, and FOSL2 knockdown suppresses luciferase activity and reduces H3K27ac enrichment within the SE region.",{"name":119,"@type":110,"acceptedAnswer":120},"Through what signaling pathway does EFNA1 promote tumor progression?",{"text":121,"@type":113},"EFNA1 cis-interacts with EphA2, decreases EphA2 tyrosine phosphorylation, and leads to subsequent activation of the Src/AKT/STAT3 forward signaling pathway, which pathway inhibitors can attenuate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370461,1790866803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nSuper-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis  \nShu-Qiang Liu,1,2,3 Xi-Xi Cheng,1,3 Shuai He,1,3 Tao Xia,1,3 Yi-Qi Li,1,3 Wan Peng,1,3 Ya-Qing Zhou,1,3 Zi-Hao Xu,1,3 Mi-Si He,4 Yang Liu,1,3 Pan-Pan Wei,1,3 Song-Hua Yuan,5 Chang Liu,2 Shu-Lan Sun,2 Dong-Ling Zou,4 Min Zheng,1 Chun-Yan Lan,1 Chun-Ling Luo,1,3 and Jin-Xin Bei1,2,3,6,7,8  \n1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. 2Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China. 3Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China. 4Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China. 5Department of Gynecology, The First People’s Hospital of Foshan, Foshan, China. 6Department of Medical Oncology, National Cancer Centre Singapore, Singapore. 7Sun Yat-sen University Institute of Advanced Studies Hong Kong, Science Park, Hong Kong, China. 8Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.  \nSuper-enhancers (SEs) are expansive cis-regulatory elements known for amplifying oncogene expression across  \nvarious cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cisinteracted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.  \nIntroduction  \nCervical cancer (CC) remains a remarkable global health challenge, ranking as the fourth most prevalent cancer and the fourth leading cause of cancer-related mortality among women worldwide (1, 2) . Multiple factors contribute to the development of CC, including infections by high-risk human papillomavirus (HPV) subtypes (3), genetic susceptibility (4), and environmental risk exposures (5) . While radical surgery or chemoradiotherapy has shown success in treating early-stage CC, late-stage diagnosis often results in poor prognosis, with a 5-year survival rate as low as 16.5% for patients with recurrent or metastatic disease (6) . Therefore, a deeper understanding of the molecular mechanisms driving cervical carcinogenesis is essential for developing more effective diagnostic and therapeutic strategies.  \nSuper-enhancers (SEs) are clusters of enhancer regions characterized by high densities of enhancer-associated histone modifications,  \nAuthorship note: SQL, XXC, and SH contributed equally to the work.  \nConflict of interest: The authors have declared that no conflict of interest","cbCaidQqTPLdpp9R","https://ap.wps.com/l/cbCaidQqTPLdpp9R","pdf",14988339,"English","# Introduction\n## Super-enhancers and cervical cancer background\n# Results and mechanisms\n## EFNA1 tumor-specific super-enhancer\n## FOSL2 regulation and chromatin enrichment\n## EFNA1 oncogenic effects and EphA2-Src/AKT/STAT3 signaling","[{\"question\":\"What discovery does the study make about super-enhancers in cervical cancer?\",\"answer\":\"It identifies a tumor-specific super-enhancer at the EFNA1 locus that drives EFNA1 expression in cervical cancer.\"},{\"question\":\"How does FOSL2 regulate the EFNA1 super-enhancer?\",\"answer\":\"The EFNA1-SE region contains FOSL2 consensus sequences, and FOSL2 knockdown suppresses luciferase activity and reduces H3K27ac enrichment within the SE region.\"},{\"question\":\"Through what signaling pathway does EFNA1 promote tumor progression?\",\"answer\":\"EFNA1 cis-interacts with EphA2, decreases EphA2 tyrosine phosphorylation, and leads to subsequent activation of the Src/AKT/STAT3 forward signaling pathway, which pathway inhibitors can attenuate.\"}]","Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis | PDF",1790188658,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/995e028677c49a52808cc69ddd95852b.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d1a70ae7c0f88e089bf5cf6b732fb5f.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9427303ebccd4976ca31c891583eae87.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/759836d78529d6b65574c13132333b06.webp",980,1311]